Detection Kit Unlock the power of precision oncology with our MSI kit—designed to detect genomic instability in colorectal and other cancers. Fast, reliable, and compatible with FFPE and plasma samples, our kit delivers reproducible results for confident clinical decisions.
FoulTa Health is dedicated to advancing human and community well‑being through innovation in molecular diagnostics, probiotics, and immunology‑based therapeutics.
Clinical Implications of MSI Test:
Colorectal & Endometrial Cancer Screening
Detects tumors with high microsatellite instability (MSI‑H), often linked to Lynch syndrome, prompting genetic counseling and family screening.
Therapeutic Decision‑Making
MSI‑H/dMMR (deficient mismatch repair) status predicts response to immune checkpoint inhibitors such as pembrolizumab, nivolumab, and ipilimumab.
Prognostic Value
In colorectal cancer, MSI‑H often correlates with better overall prognosis in early‑stage disease.
Avoidance of Ineffective Chemotherapy
Stage II MSI‑H colorectal cancer patients typically do not benefit from 5‑FU–based adjuvant chemotherapy.
Broader Tumor Profiling
MSI testing is valuable beyond colorectal cancer — e.g., in gastric, endometrial, pancreatic, prostate, and other tumor types associated with dMMR.
Guidance in Immunotherapy Accessibility
MSI‑H status can grant eligibility for tumor‑agnostic FDA‑approved immunotherapies, regardless of tumor site.
Support for Precision Medicine Pathways
Integrates into molecular pathology workflows to personalize treatment strategies and prognostic assessments.
🧬 تست MSI (ناپایداری میکروستلایت) — گامی مهم برای درمان دقیق سرطان
🔍 تست MSI چیست؟ MSI یک نشانگر ژنتیکی مهم است که در اثر نقص در سیستم ترمیم عدم تطابقDNA ایجاد می‌شود و در سرطان‌هایی مانند کولورکتال، آندومتر، معده، تخمدان، پروستات و پستان دیده می‌شود. این نقص باعث تغییر طول توالی‌های تکراری DNA (میکروستلایت‌ها) و افزایش جهش‌های ژنی می‌شود.